Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) ...

With chronic kidney disease projected to be the fifth leading cause of death by 2040, Nephrologist Dr. Adrian Sawyer is calling on the government and health officials to lead the ...

In patients with CKD, hyperkalemia significantly increases risk for major adverse cardiovascular events and arrhythmia.

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

A new review highlights how gut microbiome imbalances contribute to cardiovascular disease by altering short-chain fatty ...

Most patients received sodium-glucose co-transporter-2 inhibitors and renin-angiotensin-aldosterone system inhibitors ... cohort of patients with another kidney condition called immunoglobulin ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for its lead new drug candidate.

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in a pair of clinical trials.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...

A health expert has warned people who regularly wake up in the middle of the night to book an appointment with a doctor.